Literature DB >> 10223932

In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae.

T A Davies1, G A Pankuch, B E Dewasse, M R Jacobs, P C Appelbaum.   

Abstract

The ability of 50 sequential subcultures in subinhibitory concentrations of ciprofloxacin, levofloxacin, grepafloxacin, sparfloxacin, trovafloxacin, and amoxicillin-clavulanate to select for resistance was studied for six penicillin-susceptible and four penicillin-intermediate pneumococci. Subculturing in ciprofloxacin, grepafloxacin, levofloxacin, and sparfloxacin led to selection of mutants requiring increased MICs for all 10 strains, with MICs rising from (i) 0.5 to 4.0 to (ii) 4.0 to 32.0 microgram/ml after 7 to 12 passages for ciprofloxacin, from (i) 0.06 to 0.25 to (ii) 0.5 to 8.0 microgram/ml after 5 to 23 passages for grepafloxacin, from (i) 0.5 to 1.0 to (ii) 4.0 to 64 microgram/ml after 14 to 49 passages for levofloxacin, and from (i) 0.125 to 0.25 to (ii) 1.0 to 16.0 microgram/ml after 8 to 26 passages for sparfloxacin. Subculturing in trovafloxacin led to increased MICs for eight strains, with MICs rising from (i) 0.06 to 0.125 to (ii) 0.5 to 8.0 microgram/ml after 6 to 28 passages. Subculturing in amoxicillin-clavulanate led to raised MICs for only one strain, with the MIC rising from 0.015 to 0. 125 microgram/ml after 24 passages. Double mutations in both ParC and GyrA led to high-level quinolone resistance when ParC mutations were at S79. Trovafloxacin MICs were 1 to 2 microgram/ml in double mutants with ParC mutations at positions other than S79 (e.g., D83). Mutations in ParE (at D435, R447, and E474) and GyrB (at S405, D406, and D435) were found in four and six mutants, respectively. In the presence of reserpine, 29 mutants had lower ciprofloxacin MICs (2 to 16 times lower), 8 mutants had lower levofloxacin MICs (2 times), and one mutant had a lower trovafloxacin MIC (2 times), suggesting the involvement of an efflux mechanism. In contrast to the case for quinolones, subculturing in the presence of amoxicillin-clavulanate did not select for resistance to this drug.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10223932      PMCID: PMC89129     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Apparent involvement of a multidrug transporter in the fluoroquinolone resistance of Streptococcus pneumoniae.

Authors:  N N Baranova; A A Neyfakh
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

Review 2.  Drug-resistant Streptococcus pneumoniae.

Authors:  G D Campbell; R Silberman
Journal:  Clin Infect Dis       Date:  1998-05       Impact factor: 9.079

Review 3.  New quinolones and gram-positive bacteria.

Authors:  L J Piddock
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

4.  Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.

Authors:  X S Pan; L M Fisher
Journal:  J Bacteriol       Date:  1996-07       Impact factor: 3.490

5.  Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones.

Authors:  H Yoshida; M Bogaki; S Nakamura; K Ubukata; M Konno
Journal:  J Bacteriol       Date:  1990-12       Impact factor: 3.490

Review 6.  Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors:  P C Appelbaum
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

7.  Susceptibility of penicillin-sensitive and -resistant strains of Streptococcus pneumoniae to new antimicrobial agents, including daptomycin, teicoplanin, cefpodoxime and quinolones.

Authors:  P C Appelbaum; S K Spangler; E Crotty; M R Jacobs
Journal:  J Antimicrob Chemother       Date:  1989-04       Impact factor: 5.790

8.  In vitro selection of resistance to four beta-lactams and azithromycin in Streptococcus pneumoniae.

Authors:  G A Pankuch; S A Jueneman; T A Davies; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

Review 9.  Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.

Authors:  J P Thys; F Jacobs; B Byl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

10.  In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.

Authors:  A E Girard; D Girard; T D Gootz; J A Faiella; C R Cimochowski
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

View more
  36 in total

1.  New mutation in parE in a pneumococcal in vitro mutant resistant to fluoroquinolones.

Authors:  C Janoir; E Varon; M D Kitzis; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.

Authors:  M Boos; S Mayer; A Fischer; K Köhrer; S Scheuring; P Heisig; J Verhoef; A C Fluit; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

3.  Decreased Susceptibility of Streptococcus pneumoniae to Fluoroquinolones: A Growing Concern.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-04       Impact factor: 3.725

4.  In vitro development of resistance to ofloxacin and doxycycline in Bacillus anthracis Sterne.

Authors:  C H Choe; S S Bouhaouala; I Brook; T B Elliot; G B Knudson
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

5.  Antipneumococcal activity of BMS 284756 compared to those of six other agents.

Authors:  Glenn A Pankuch; Kensuke Nagai; Todd A Davies; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

6.  Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae.

Authors:  Paul F Riska; Andrei Kutlin; Patrick Ajiboye; Arnold Cua; Patricia M Roblin; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  Antipneumococcal activities of gemifloxacin compared to those of nine other agents.

Authors:  T A Davies; L M Kelly; G A Pankuch; K L Credito; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

8.  Global transcriptome analysis of the responses of a fluoroquinolone-resistant Streptococcus pneumoniae mutant and its parent to ciprofloxacin.

Authors:  Estelle Marrer; A Tatsuo Satoh; Margaret M Johnson; Laura J V Piddock; Malcolm G P Page
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

9.  Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.

Authors:  Klaudia Kosowska-Shick; Kim Credito; Glenn A Pankuch; Gengrong Lin; Bülent Bozdogan; Pamela McGhee; Bonifacio Dewasse; Dong-Rack Choi; Jei Man Ryu; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

10.  Involvement of the putative ATP-dependent efflux proteins PatA and PatB in fluoroquinolone resistance of a multidrug-resistant mutant of Streptococcus pneumoniae.

Authors:  Estelle Marrer; Karen Schad; Andreas T Satoh; Malcolm G P Page; Maggie M Johnson; Laura J V Piddock
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.